Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: A rationale for the EMPAKIDNEY study (Clinical Kidney Journal (2018) 11:6 (749-761) DOI: 10.1093/ckj/sfy090);The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: A rationale for the EMPA-KIDNEY study

Clinical Kidney Journal

Volumn 11, Issue 6, 2018, Pages 749-761

  Herrington, William G ^a   Preiss, David ^a   Haynes, Richard ^a   Von Eynatten, Maximilian ^b   Staplin, Natalie ^a,c   Hauske, Sibylle J ^b   George, Jyothis T ^b   Green, Jennifer B ^d   Landray, Martin J ^a,c   Baigent, Colin ^a   Wanner, Christoph ^e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Cardiovascular; CKD; Clinical trial; Diabetic kidney disease; SGLT 2 inhibitor

Indexed keywords

GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ADVERSE EVENT; ALBUMINURIA; BLOOD PRESSURE; BODY FAT; BODY FLUID; CARDIO RENAL OUTCOME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CHRONIC KIDNEY FAILURE; CLINICAL OUTCOME; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; GLUCOSE URINE LEVEL; GLUCOSURIA; GLYCEMIC CONTROL; HOMEOSTASIS; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL SYSTEM PARAMETERS; REVIEW;

EID: 85062027969     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/CKJ/SFZ009     Document Type: Erratum

References (93)

1. Levey AS, Coresh J. Chronic kidney disease. Lancet 2012; 379: 165-80
2. Stevens PE, O'Donoghue DJ, de Lusignan S et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 2007; 72: 92-99
3. Hoerger TJ, Simpson SA, Yarnoff BO et al. The future burden of CKD in the United States: a simulation model for the CDC CKD Initiative. Am J Kidney Dis 2015; 65: 403-411
4. Jha V, Garcia-Garcia G, Iseki K et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013; 382: 260-272
5. US Renal Data System. USRDS. 2014 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2014, 2
6. Fox CS, Matsushita K, Woodward M et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380: 1662-1673
7. Kent S, Schlackow I, Lozano-Kühne J et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? BMC Nephrol 2015; 16: 65
8. Kerr M, Bray B, Medcalf J et al. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant 2012; 27(Suppl 3): iii73-iii80
9. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-2081
10. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87
11. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
12. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
13. Fried LF, Emanuele N, Zhang JH et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369: 1892-1903
14. Zoungas S, Arima H, Gerstein HC et al. The effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017; 5: 431-437
15. Herrington WG, Preiss D. Tightening our understanding of intensive glycaemic control. Lancet Diabetes Endocrinol 2017; 5: 405-407
16. de Boer IH. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014; 37: 24-30
17. Zoungas S, Chalmers J, Neal B et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014; 371: 1392-1406
18. Klahr S, Levey AS, Beck GJ et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330: 877-884
19. Lv J, Ehteshami P, Sarnak MJ et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 2013; 185: 949-957
20. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431
21. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957-967
22. Herrington W, Emberson J, Mihaylova B, et al. How are the effects of reducing LDL cholesterol with a statin-based regime influenced by renal function? Meta-analysis of individual data from 28 randomised trials. Lancet Diabetes Endocrinol 2016; 4: 829-839
23. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Guideline Development Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl 2013; 3: 263-26
24. National Institute for Health and Clinical Excellence. Clinical Guidance: Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. http://www.nice.org.uk/guidance/cg181 (8 April 2018, date last accessed)
25. Park M, Hsu C-Y, Li Y et al. Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol 2012; 23: 1725-1734
26. Foley RN, Parfrey PS, Kent GM et al. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 1998; 54: 1720-1725
27. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134
28. Ninomiya T, Perkovic V, Turnbull F et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ 2013; 347: f5680
29. Metra M, Teerlink JR. Heart failure. Lancet 2017; 390: 1981-1995
30. Bakris GL, Fonseca VA, Sharma K et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009; 75: 1272-1277
31. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657
32. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128
33. Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-334
34. Liu JJ, Lee T, DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 2012; 61: 2199-2204
35. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010; 5: 133-141
36. Wang XX, Levi J, Luo Y et al. SGLT2 protein expression is increased in human diabetic nephropathy. J Biol Chem 2017; 292: 5335-5348
37. Alicic RZ, Johnson EJ, Tuttle KR. SGLT2 inhibition for the prevention and treatment of diabetic kidney disease: a review. Am J Kidney Dis 2018; 72: 267-277
38. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 2017; 60: 215-225
39. Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes 2013; 62: 3324-3328
40. Striepe K, Jumar A, Ott C et al. Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus. Circulation 2017; 136: 1167-1169
41. Heerspink HJ, Perkins BA, Fitchett DH et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016; 134: 752-772
42. Butler J, Hamo CE, Filippatos G et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail 2017; 19: 1390-1400
43. Tonneijck L, Muskiet MHA, Smits MM et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol 2017; 28: 1023-1039
44. Cherney DZI, Zinman B, Inzucchi SE et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5: 610-621
45. Perkovic V, de Zeeum D, Mahaffey KW et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol 2018; 6: 691-704
46. Lorenz JN, Weihprecht H, Schnermann J et al. Renin release from isolated juxtaglomerular apparatus depends on macula densa chloride transport. Am J Physiol 1991; 260(4 Pt 2): F486-F493
47. Verbrugge FH, Dupont M, Steels P et al. The kidney in congestive heart failure: 'are natriuresis, sodium, and diuretics really the good, the bad and the ugly?'. Eur J Heart Fail 2014; 16: 133-142
48. Palatini P. Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension. Nephrol Dial Transplant 2012; 27: 1708-1714
49. Ogna A, Forni Ogna V, Bochud M et al. Association between obesity and glomerular hyperfiltration: the confounding effect of smoking and sodium and protein intakes. Eur J Nutr 2016; 55: 1089-1097
50. Helal I, Fick-Brosnahan GM, Reed-Gitomer B et al. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol 2012; 8: 293-300
51. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996; 49: 1774-1777
52. Haynes R, Staplin N, Emberson J et al. Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP). Am J Kidney Dis 2014; 64: 40-48
53. Perico N, Ruggenenti P, Remuzzi G. ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease. Curr Opin Pharmacol 2017; 33: 34-40
54. Ferrannini E, Baldi S, Frascerra S et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 2016; 65: 1190-1195
55. Al-Jobori H, Daniele G, Cersosimo E et al. Empagliflozin and kinetics of renal glucose transport in healthy individuals and individuals with type 2 diabetes. Diabetes 2017; 66: 1999-2006
56. Bays HE, Weinstein R, Law G et al. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) 2014; 22: 1042-1049
57. Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open 2016; 6: e009417
58. Vasilakou D, Karagiannis T, Athanasiadou E et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159: 262-274
59. Ferrannini E, Ramos SJ, Salsali A et al. Dapagliflozin mono-therapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217-2224
60. Roden M, Weng J, Eilbracht J et al. Empagliflozin monother-apy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013; 1: 208-219
61. Petrykiv S, Sjostrom CD, Greasley PJ et al. Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin J Am Soc Nephrol 2017; 12: 751-759
62. Cherney DZI, Cooper ME, Tikkanen I et al. Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int 2018; 93: 231-244
63. Sha S, Devineni D, Ghosh A et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011; 13: 669-672
64. Devineni D, Curtin CR, Polidori D et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 2013; 53: 601-610
65. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015; 100: 2849-2852
66. Baker WL, Smyth LR, Riche DM et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014; 8: 262-275.e9
67. Ridderstråle M, Andersen KR, Zeller C et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2: 691-700
68. Ferrannini G, Hach T, Crowe S et al. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; 38: 1730-1735
69. Kohan DE, Fioretto P, Tang W et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014; 85: 962-971
70. Hallow KM, Helmlinger G, Greasley PJ et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab 2018; 20: 479-487
71. Mancia G, Cannon CP, Tikkanen I et al. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension 2016; 68: 1355-1364
72. Heerspink HJ, Desai M, Jardine M et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2017; 28: 368-375
73. Neuen BL, Ohkuma T, Neal B, et al. Canagliflozin and Renal Outcomes in Patients with Chronic Kidney Disease. Poster at the National Kidney Federation Spring Clinical Meetings - April 10-14 2018, Austin, Texas. http://jgl_nkf2018.scientificpresenta tions.org/Neuen_JGL63181.pdf (13 April 2018, date last accessed)
74. Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic Nephropathy (CREDENCE). https://clinicaltrials.gov/ct2/show/ NCT02065791 (29 August 2017, date last accessed)
75. Jardine MJ, Mahaffey KW, Neal B et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 2017; 46: 462-472
76. Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA (Canagliflozin) is Being Stopped Early for Postive Efficacy Findings. https://www.janssen.com/phase-3-credence-renal-out comes-trial-invokanar-canagliflozin-being-stopped-early-positive-efficacy (6 August 2018, date last accessed)
77. A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Partients with Chronic Kidney Disease (Dapa-CKD). https://clinicaltrials.gov/ct2/show/ NCT03036150 (29 August 2017, date last accessed)
78. Staels B. Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms. Am J Med 2017; 130: S30-S39
79. Aubert G, Martin OJ, Horton JL et al. The failing heart relies on ketone bodies as a fuel. Circulation 2016; 133: 698-705
80. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011; 8: 30-41
81. Fang JC. Heart failure with preserved ejection fraction: a kidney disorder? Circulation 2016; 134: 435-437
82. www.empakidney.org (10 September 2018, date last accessed)
83. Empagliflozin (JardianceVR) to be studied in chronic kidney disease. https://www.boehringer-ingelheim.com/press-release/emp agliflozin-be-studied-chronic-kidney-disease (29 August 2017, date last accessed)
84. VR trial. Eur Heart J 2018; 39: 363-370
85. Inzucchi SE, Zinman B, Fitchett D et al. How does empagliflozin reduce cardiovascular mortality? insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 2018; 41: 356-363
86. Wanner C, Lachin JM, Inzucchi SE et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes, established cardiovascular disease and chronic kidney disease. Circulation 2017; 132: 119-129
87. Kohler S, Zeller C, Iliev H et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of Phase I-III clinical trials. Adv Ther 2017; 34: 1707-1726
88. Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved). https://clinicaltrials.gov/ct2/show/NCT03057951 (29 August 2017, date last accessed)
89. Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Reduced Ejection Fraction (EMPEROR-Reduced). https://clinicaltrials.gov/ct2/show/NCT03057977 (29 August 2017, date last accessed)
90. Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (Dapa-HF). https://clinicaltrials.gov/ct2/show/NCT03036124 (29 August 2017, date last accessed)
91. Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58). https://clinicaltrials.gov/ct2/show/NCT01730534 (29 August 2017, date last accessed)
92. Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004). https://clinicaltrials.gov/ct2/show/NCT01986881 (12 September 2017, date last accessed)
93. Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk (SCORED). https://clinicaltrials.gov/ct2/show/NCT03315143 (19 June 2018, date last accessed)